KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Edwards Lifesciences (EW) Long-Term Debt Issuances (2016 - 2021)

Edwards Lifesciences has reported Long-Term Debt Issuances over the past 11 years, most recently at -$8.8 million for Q3 2021.

  • Quarterly results put Long-Term Debt Issuances at -$8.8 million for Q3 2021, down 617.65% from a year ago — trailing twelve months through Jun 2022 was -$8.8 million (down 144.9% YoY), and the annual figure for FY2021 was $5.2 million, down 67.9%.
  • Long-Term Debt Issuances for Q3 2021 was -$8.8 million at Edwards Lifesciences, down from $9.5 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for EW hit a ceiling of $608.0 million in Q2 2017 and a floor of -$8.8 million in Q3 2021.
  • Median Long-Term Debt Issuances over the past 5 years was $4.5 million (2021), compared with a mean of $86.4 million.
  • Biggest five-year swings in Long-Term Debt Issuances: skyrocketed 9706.45% in 2017 and later plummeted 617.65% in 2021.
  • Edwards Lifesciences' Long-Term Debt Issuances stood at $5.4 million in 2017, then plummeted by 70.37% to $1.6 million in 2018, then soared by 331.25% to $6.9 million in 2019, then crashed by 43.48% to $3.9 million in 2020, then plummeted by 325.64% to -$8.8 million in 2021.
  • The last three reported values for Long-Term Debt Issuances were -$8.8 million (Q3 2021), $9.5 million (Q2 2021), and $4.5 million (Q1 2021) per Business Quant data.